

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 478.1072
INTERNATIONAL APPLICATION NO. PCT/GB2004/001627		INTERNATIONAL FILING DATE 14 April 2004 (14.04.2004)
TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS COMPRISING APOMORPHINE FOR PULMONARY INHALATION		PRIORITY DATE CLAIMED 14 April 2003 (14.04.2003)
APPLICANT(S) FOR DO/EO/US Nicholas John STANIFORTH, David MORTON, Michael TOBYN, Stephen EASON, Quentin HARMER and David GANDERTON		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Datasheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: 		
Letter re: Priority; International Search Report		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (known, see 37 C.F.R. 1.50) 10/552231		INTERNATIONAL APPLICATION NO. PCT/GB2004/001627		ATTORNEY'S DOCKET NO. 36,561	
The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21.	<input checked="" type="checkbox"/>	Basic national fee.....	\$300	\$ 300.00	
22.	<input checked="" type="checkbox"/>	Examination fee			
If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 333(1)-(4).....				\$ 200.00	
All other situations					
23.	<input checked="" type="checkbox"/>	Search fee			
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority				\$ 400.00	
International Search Report prepared and provided to the Office					
All other situations					
TOTAL OF 21, 22 and 23 =				\$	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	/50 =		x \$250 =	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).....				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	45 - 20 =	25	x \$50 =	\$ 1250.00	
Independent Claims	1 - 3 =	0	x \$200 =	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360 +	\$ 0	
TOTAL OF ABOVE CALCULATIONS =				\$ 2150.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 C.F.R. 1.27. Fees above are reduced by 1/2.				\$	
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 2150.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 2150.00	
				Amount to be refunded:	\$
				Amount to be charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$2150.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0552 . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, NY 10018 (212)-736-1940 Dated: October 6, 2005					
				SIGNATURE	
				Cary S. Kappel	
				NAME	
				36,561	
				REGISTRATION NUMBER	

10/552231

JCO9 Rec'd PCT/PTO 06 OCT 2005

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Nicholas John STANIFORTH, et al.

Docket No. 478.1072

Serial No. PCT/GB2004/001627	Filing Date 14 April 2004	Examiner To Be Assigned	Group Art Unit To Be Assigned
---------------------------------	------------------------------	----------------------------	----------------------------------

Invention: **PHARMACEUTICAL COMPOSITIONS COMPRISING APOMORPHINE FOR PULMONARY INHALATION**

I hereby certify that the following correspondence:

Application Filed Under 35 U.S.C. 371 with Accompanying Documents.

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 6, 2005

(Date)

Errick Smalls

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

EV 382 790 385 US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

478.1072

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Re: Application of: **Nicholas John STANIFORTH, et al.**
Serial No.: **To Be Assigned**
Filed: Herewith as national phase of International Application
No. PCT/GB2004/001627, filed April 14, 2004
For: **PHARMACEUTICAL COMPOSITIONS
COMPRISING APOMORPHINE FOR PULMONARY
INHALATION**

LETTER RE: PRIORITY

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 6, 2005

Sir:

Applicant hereby claims priority from U.S. Patent Application Serial No. 10/413,022, filed April 14, 2004, and from U.S. Patent Application Serial No. 10/621,964, filed July 17, 2003, through PCT/GB2004/001627, filed April 14, 2004.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Cary S. Kappel
Reg. No. 36,561

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940